Bavarian Nordic A/S רווח 2024

מה עושה Bavarian Nordic A/S?

Bavarian Nordic A/S is a biopharmaceutical company based in Denmark, specializing in the development and production of vaccines. The company was established in 1994 as a spin-off from the University of Copenhagen and has been listed on the Copenhagen stock exchange since 1998. The company's history began with an innovation developed by Professor Peter Andersen at the University of Copenhagen - the Viruslike Particles (VLP) technology. This technology serves as the basis for the production of vaccines against severe infectious diseases such as influenza, RSV, or HPV. Bavarian Nordic utilizes this technology to generate effective immune responses without using live pathogens. The company's business model is focused on two areas: the commercial vaccine sector and the biodefense products sector. The commercial sector includes the development and production of vaccines for cancer (such as prostate cancer or breast cancer) as well as infectious diseases like RSV. The biodefense products sector concentrates on protection against biological attacks, with the company manufacturing vaccines against bioweapons such as anthrax or smallpox for governmental institutions. Bavarian Nordic is divided into various business divisions. One of these is the commercial vaccines department, which develops and produces vaccines for the commercial market, particularly for cancer indications. The company also has a biodefense products department, which safeguards governmental institutions and organizations against bioterrorist attacks and other threats posed by biological weapons. This department focuses on the development and production of vaccines against smallpox, anthrax, and Ebola virus. Bavarian Nordic offers a wide range of products. The commercial vaccine Prostvac against prostate cancer is the company's flagship product. Other vaccines that have been developed or are still in development include vaccines against breast cancer, influenza, RSV, and lung cancer. The biodefense products encompass vaccines against smallpox, anthrax, and Ebola virus, as well as preclinical development programs for additional biological attacks. The company has also signed cooperation agreements with other companies to accelerate the research and development of new products. These include collaborations with Bristol Myers Squibb and Janssen Pharmaceutica for the development of cancer vaccines, as well as with the British Ministry of Defence for the development of vaccines against anthrax. Overall, Bavarian Nordic A/S caters to a broad range of interests and business sectors. The company focuses on the development and production of vaccines for both commercial and governmental institutions, aiming to enhance protection against biological threats and infectious diseases. Thanks to its innovative VLP technology, the company is a key player in the field of vaccine development and offers a wide range of products. Bavarian Nordic A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.